Impax Pharmaceuticals, a division of Impax Laboratories, Inc. has announced the resubmission of Impax's New Drug Application (NDA) for Rytary...
The FDA has approved Rytary (extended-release oral carbidopa-levodopa), from Impax Pharma, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and...
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. has announced that the FDA has issued a Complete Response Letter regarding...
Allergan has filed an Abbreviated New Drug Application with the FDA seeking approval to market carbidopa and levodopa extended-release capsules,...
Impax Laboratories, Inc.announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted...